IL286727A - Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma - Google Patents

Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Info

Publication number
IL286727A
IL286727A IL286727A IL28672721A IL286727A IL 286727 A IL286727 A IL 286727A IL 286727 A IL286727 A IL 286727A IL 28672721 A IL28672721 A IL 28672721A IL 286727 A IL286727 A IL 286727A
Authority
IL
Israel
Prior art keywords
treatment
tyrosine kinase
kinase inhibitors
urinary tract
tract carcinoma
Prior art date
Application number
IL286727A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL286727A publication Critical patent/IL286727A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
IL286727A 2019-03-29 2021-09-26 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma IL286727A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
US201962833395P 2019-04-12 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
IL286727A true IL286727A (en) 2021-10-31

Family

ID=69954076

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286727A IL286727A (en) 2019-03-29 2021-09-26 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Country Status (15)

Country Link
US (1) US20220175768A1 (cg-RX-API-DMAC7.html)
EP (2) EP3946340A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022527482A (cg-RX-API-DMAC7.html)
KR (1) KR20210143878A (cg-RX-API-DMAC7.html)
CN (1) CN113645975A (cg-RX-API-DMAC7.html)
AU (1) AU2020253054B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019203A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130773A1 (cg-RX-API-DMAC7.html)
IL (1) IL286727A (cg-RX-API-DMAC7.html)
JO (1) JOP20210260A1 (cg-RX-API-DMAC7.html)
MA (1) MA55486A (cg-RX-API-DMAC7.html)
MX (1) MX2021011943A (cg-RX-API-DMAC7.html)
PH (1) PH12021552352A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109854RA (cg-RX-API-DMAC7.html)
WO (1) WO2020201138A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
WO2022243467A1 (en) * 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
AU2022289906A1 (en) * 2021-06-07 2023-11-09 R.P. Scherer Technologies, Llc Protective coating for moisture sensitive pharmaceutical compositions
IL312063A (en) 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
WO2023159216A1 (en) 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
CN116106240B (zh) * 2022-12-26 2025-11-07 华中农业大学 一种尿液酪氨酸检测体系、检测方法及检测试剂盒
IL322667A (en) 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
CN120731077A (zh) 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Also Published As

Publication number Publication date
EP4548935A3 (en) 2025-08-06
JP2026048748A (ja) 2026-03-17
MX2021011943A (es) 2021-11-03
MA55486A (fr) 2022-02-09
PH12021552352A1 (en) 2022-09-05
SG11202109854RA (en) 2021-10-28
EP3946340A1 (en) 2022-02-09
AU2020253054A1 (en) 2021-09-30
JP2022527482A (ja) 2022-06-02
CA3130773A1 (en) 2020-10-08
WO2020201138A1 (en) 2020-10-08
BR112021019203A2 (pt) 2021-11-30
KR20210143878A (ko) 2021-11-29
EP4548935A2 (en) 2025-05-07
CN113645975A (zh) 2021-11-12
AU2020253054B2 (en) 2026-01-08
JOP20210260A1 (ar) 2023-01-30
US20220175768A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
IL279258B (en) tyrosine kinase inhibitors
MA55486A (fr) Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
SG11201607706SA (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
EP3399968B8 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EP3648753A4 (en) SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
IL283599A (en) Tyrosine kinase inhibitors, preparations and methods
EP3962908A4 (en) HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
EP3448852A4 (en) NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
EP3226869A4 (en) Kinase inhibitor prodrug for the treatment of cancer
EP4169918B8 (en) Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
DK3972604T3 (da) Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria
EP3328496A4 (en) Inhibitors of ack1/tnk2 tyrosine kinase
MX393992B (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa
IL286729A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
IL290798A (en) Prodrugs of the tyrosine kinase inhibitor for treating cancer
EP3999064A4 (en) Inhibitors of tyrosine kinase
GB201807845D0 (en) Kinase Inhibitors
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
HK40068921A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40068919A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
ES3065589T3 (en) Tyrosine kinase inhibitors
IL272887A (en) A pharmaceutical preparation containing a selective inhibitor of FGFR tyrosine kinase